Register for our free email digests:
Latest From Bracco SPA
Pharmaceutical revenues were down slightly; so was R&D spending, thanks to a strengthening dollar. Scrip analyzes 620 companies and uses numbers, clocks and tiers to paint some data pictures of the pharmaceutical industry in 2015.
Keeping Track: Chugai Delivers Two Breakthroughs For Roche; FDA Continues To Wrestle With Opioid Regulation
The latest drug development news and highlights from our FDA Performance Tracker.
EnteroMedics Inc., a company developing medical devices, has appointed Dan Gladney president and CEO – effective Nov. 16, 2015. Gladney has also been appointed to the company's board. Current president, CEO and chair of EnteroMedics, Mark Knudson, will remain its executive chair until the beginning of 2016, when he will become non-executive chair of the company's board. Most recently Gladney was director and CEO of Lanx Inc., a medical device company, which was later acquired by Biomet Inc. Prior to Lanx, Gladney was healthcare operating partner at Norwest Equity Partners and prior to this, he was president and CEO of various companies including Heart Leaflet Technologies and ACIST Medical Systems, both of which were acquired by The Bracco Group.
The Swiss medical agency Swissmedic has recommended against approval of San Diego-based Apricus Biosciences' erectile dysfunction product Vitaros (alprostadil) due to "quality related issues" issues with the drug's shelf life. This is in spite of the fact that the agency was happy with the company's data.
- Therapeutic Areas
- Western Europe
- Company Type
- Midsize European
- Parent & Subsidiaries
- Bracco SPA
- Senior Management
- Diana Bracco, Pres. & CEO
- Contact Info
Phone: (39) 0221771
Via XXV Aprile, 4
San Donato Milanese, 20097
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.